Medical Developments International Ltd rises 3% on Walgreens deal

The Medical Developments International Ltd (ASX: MVP) share price has risen 3% today after announcing an exciting deal.

Management announced that it has finalised a ‘ranging’ deal with Walgreens in the USA. Walgreens is the second largest pharmacy store chain in the US, with nearly 9,000 outlets. Walgreens Boots Alliance Inc is the largest pharmacy business in the world.

In addition to finalising the deal, Walgreens placed the first order for stock and is distributing Medical Development product onto the pharmacy shelves.

The deal is to supply the Compact Anti-Static Space Chamber to 2,000 Walgreens stores, which will be supplied through AmerisourceBergen. Management expect the deal will grow the Space Chamber category in the 2,000 allocated stores and create a case for its products to be rolled out to all Walgreens stores.

Medical Developments CEO, John Sharman, said “Medical Developments has been working towards securing a Ranging deal from Walgreens for almost two years. In addition to Walgreens, we recently added 235 stores from the Meijer pharmacy store chain in the US. This deal is for three products from the Compact Anti-Static Space Chamber range to be placed in every store, via McKesson”.

“Part of the reason Walgreens entered this deal is because we are gaining rapid acceptance for the quality of our product and our product offering amongst pharmacies in the USA. We have a world class respiratory system device product range and we have a significant price and reimbursement advantage over competitor products in the USA. We are confident our USA business will deliver the expected sales growth in the future”.

Foolish takeaway

This is yet another positive update from Medical Developments and it looks like it is on course for rapid earnings growth over the next few years.

The major issue I’d have with investing today is its huge valuation, it’s currently trading at 252x FY17’s earnings. According to analysts’ estimates it could be trading at 31x FY20’s earnings, which still isn’t cheap. It also comes with a grossed-up dividend yield of 0.73%.

If Medical Developments is too expensive for you, then these top stocks should seem much better value.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.